In addition, metformin, a commonly used drug for treating diabetes, has exerted potent inhibitory effect in tumor growth through targeting SREBP-1c and its downstream target FASN, thus inhibiting lipogenesis in bladder cancer (Deng et al., 2021). The gene discussed is SREBF1; the disease is urinary bladder carcinoma.